Cyclosporin-A Does Not Prevent Cold Ischemia/Reperfusion Injury of Rat Livers

Tarrab, Esther; Huet, Pierre‐Michel; Brault, Antoine; Rocheleau, Bernard; Laurens, Marina; Crénesse, Dominique

doi:10.1016/j.jss.2011.04.018

Cited by 4 publications

(15 citation statements)

References 44 publications

(72 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…43 The pooled estimate (2 studies; N = 67) suggested no difference in ALT (RoM 0.61; 95% CI, 0.30-1.26; I 2 = 96%) and AST (RoM 0.58; 95% CI, 0.26-1.31; I 2 = 50.2%) with donor pretreatment (Figure S2A, SDC, http://links.lww.com/TXD/ A555). 43,45 All 3 studies not included in the pooled analysis qualitatively reported lower serum aminotransferases level for liver recipients exposed to CNIs. 44,46,47 For the single lung transplantation model, donor treatment with CNIs improved oxygenation (Pao 2 ) as measured at 3 h posttransplantation (group CNI = 344.8 ± 235 mmHg versus group control = 61.3 ± 35.8 mmHg; P = 0.01).…”

Section: Graft Functionmentioning

confidence: 98%

“…From 1267 citations, 18 studies were eligible for this review (Figure 1) and included descriptions of >500 animals (Table 1). [23][24][25][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51] κ agreement for study selection was 0.77. All studies were published between 1991 and 2020.…”

Section: Study Selectionmentioning

confidence: 99%

“…Most studies (16/18; 89%) used rat models of organ transplantation, [23][24][25][38][39][40][41][42][43][44][45][46][48][49][50][51] whereas 2 studies used pigs (Table 1). 37,47 The specific organ of interest varied and included kidney (8 studies), 23,25,[37][38][39][40][41][42] liver (6 studies), [43][44][45][46][47][48] bowel (3 studies), 24,50,51 and lung (1 study). 49 Table 1 lists the CNI regimens.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…[23][24][25]38,40,42,[44][45][46][49][50][51] Eleven studies (61%) administered a single dose. 24,25,38,[40][41][42][43]46,48,50,51 The principal routes of administration were intravenous (8/18 studies; 44%), 23,24,38,40,42,46,50,51 enteral (4 studies; 22%), 37,39,43,48 intraperitoneal (2 studies; 11%), 25,41 and intramuscular (2 studies; 11%). 45,47 The timing of CNI therapy initiation varied between studies.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Calcineurin Inhibition in Deceased Organ Donors: A Systematic Review and Meta-analysis of Preclinical Studies

D’Aragon,

Rousseau,

Breau

et al. 2023

Transplantation Direct

View full text Add to dashboard Cite

Background. Preconditioning deceased organ donors with calcineurin inhibitors (CNIs) may reduce ischemia–reperfusion injury to improve transplant outcomes. Methods. We searched MEDLINE, EMBASE, Cochrane Library, and conference proceedings for animal models of organ donation and transplantation, comparing donor treatment with CNIs with either placebo or no intervention, and evaluating outcomes for organ transplantation. Reviewers independently screened and selected studies, abstracted data, and assessed the risk of bias and clinical relevance of included studies. Where possible, we pooled results using meta-analysis; otherwise, we summarized findings descriptively. Results. Eighteen studies used various animals and a range of CNI agents and doses and evaluated their effects on a variety of transplant outcomes. The risk of bias and clinical applicability were poorly reported. Pooled analyses suggested benefit of CNI treatment on early graft function in renal transplants (3 studies; serum creatinine: ratio of means [RoM] 0.54; 95% confidence interval [CI], 0.34-0.86) but not for liver transplants (2 studies; serum alanine transaminase: RoM 0.61; 95% CI, 0.30-1.26; and serum aspartate aminotransferase: RoM 0.58; 95% CI, 0.26-1.31). We found no reduction in graft loss at 7 d (2 studies; risk ratio 0.54; 95% CI, 0.08-3.42). CNI treatment was associated with reduced transplant recipient levels of interleukin-6 (4 studies; RoM 0.36; 95% CI, 0.19-0.70), tumor necrosis factor-alpha (5 studies; RoM 0.36; 95% CI, 0.12-1.03), and cellular apoptosis (4 studies; RoM 0.30; 95% CI, 0.19-0.47). Conclusions. Although this compendium of animal experiments suggests that donor preconditioning with CNIs may improve early kidney graft function, the limited ability to reproduce a true clinical environment in animal experiments and to assess for risk of bias in these experiments is a serious weakness that precludes current clinical application.

show abstract

Section: Graft Functionmentioning

confidence: 98%

Section: Study Selectionmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Calcineurin Inhibition in Deceased Organ Donors: A Systematic Review and Meta-analysis of Preclinical Studies

D’Aragon,

Rousseau,

Breau

et al. 2023

Transplantation Direct

View full text Add to dashboard Cite

show abstract

“…This can block the activation of the apoptosis pathway by preventing mitochondrial swelling, which in turn inhibits the release of cytochrome c and the activation of the caspases. The paper by Tarrab et al [6], evaluated whether CsA could have a protective effect in preventing liver cell necrosis and apoptosis following cold ischemia/warm reperfusion (CI/WR) injury. Their research led to the unexpected result of a lack of protective effect of CsA in CI/WR injury, which also was in contrast to previous data showing a beneficial role for CsA [4,5,7].…”

mentioning

confidence: 99%